Drug search by name

Seconal Sodium and Toremifene Citrate

Determining the interaction of Seconal Sodium and Toremifene Citrate and the possibility of their joint administration.

Check result:

Seconal Sodium <> Toremifene Citrate

Relevance: 16.02.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Secobarbital may reduce the blood levels of toremifene in some patients, which may make the medication less effective. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of toremifene. According to the product labeling, toremifene is primarily metabolized by CYP450 3A4 to N-demethyltoremifene, an antiestrogenic metabolite with weak in vivo antitumor potency but whose serum concentrations are 2 to 4 times higher than those of toremifene at steady state. When a single 120 mg oral dose of toremifene was administered to 9 healthy volunteers following treatment with the potent CYP450 3A4 inducer rifampin at a dosage of 600 mg once daily for 5 days, toremifene peak plasma concentration (Cmax), systemic exposure (AUC) and elimination half-life decreased by 55%, 87% and 44%, respectively, compared to pretreatment with placebo. In addition, rifampin decreased the AUC of N-demethyltoremifene by 80% and increased its Cmax by 48%, suggesting enhanced presystemic metabolism of toremifene in the intestine. The extent to which other, less potent CYP450 3A4 inducers may affect toremifene is unknown.

MANAGEMENT: The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or a dose adjustment of toremifene may be required if an interaction is suspected.

References

Cerner Multum, Inc. "Australian Product Information." O 0
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
"Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.
Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54
Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95

Seconal Sodium

Generic Name: secobarbital

Brand name: Seconal Sodium, Seconal

Synonyms: n.a.

What is Seconal Sodium?

Toremifene Citrate

Generic Name: toremifene

Brand name: Fareston

Synonyms: Toremifene

What is Toremifene Citrate?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions